Grifols (GIFLF) Other Operating Expenses (2010 - 2024)
Grifols' (GIFLF) quarterly Other Operating Expenses came in at -$0.0 in Q4 2024, up 100.0% on a YoY basis from -$0.0 in Q1 2024, and up 100.0% quarter-over-quarter from -$1.9 billion in Q4 2023.
Analysis
Grifols (GIFLF) Other Operating Expenses (2010 - 2024) Analysis & Trends
Grifols (GIFLF) has reported Other Operating Expenses for 14 consecutive years, with -$0.0 the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Other Operating Expenses rose 100.0% year-over-year to -$0.0; the trailing twelve-month figure through Dec 2025 stood at -$1.9 billion (down 287.85% YoY), and the FY2025 full-year result was -$0.0, changed N/A from the prior year.
- Other Operating Expenses climbed to -$0.0 in Q4 2024 per GIFLF's latest filing, from -$1.9 billion in the prior quarter.
- Across five years, Other Operating Expenses topped out at $1.4 billion in Q4 2021 and bottomed at -$1.9 billion in Q4 2023.
- Historically, Other Operating Expenses has averaged $107.5 million across 4 years, with a median of -$0.0 in 2024.
- The sharpest annual moves came in 2020 and 2024: Other Operating Expenses dropped 4.15% in 2020, then soared 100.0% in 2024.
- Over 4 years, Other Operating Expenses stood at $1.4 billion in 2020, then gained by 2.28% to $1.4 billion in 2021, then plunged by 234.74% to -$1.9 billion in 2023, then jumped by 100.0% to -$0.0 in 2024.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$0.0, -$1.9 billion, and $1.4 billion for Q4 2024, Q4 2023, and Q4 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 0.00 |
| Dec 31, 2023 | -1.90 Bn |
| Dec 31, 2021 | 1.41 Bn |
| Dec 31, 2020 | 1.38 Bn |
| Mar 31, 2020 | -351.55 Mn |
| Dec 31, 2019 | 1.21 Bn |
| Mar 31, 2019 | -337.55 Mn |
| Jun 30, 2018 | 1.21 Bn |
| Mar 31, 2018 | -300.11 Mn |
| Jun 30, 2017 | -17.86 Mn |
| Mar 31, 2017 | -308.10 Mn |
| Sep 30, 2016 | 0.00 |
| Dec 31, 2015 | 1.04 Bn |
| Jun 30, 2015 | 0.00 |
| Mar 31, 2015 | -333.40 Mn |
| Dec 31, 2014 | 946.87 Mn |
| Dec 31, 2013 | 819.28 Mn |
| Dec 31, 2012 | 8.72 Mn |
| Jun 30, 2012 | 1.01 Mn |
| Mar 31, 2012 | 135,065.50 |